ArticleBreast cancer research and treatment2021
Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.
Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis.Journal of the National Cancer Institute · 2024Pooled it
- Tissue-stiffness-driven platelet activation emerges as a potential target for breast cancer prevention and treatment.Cell communication and signaling : CCS · 2026Article
- A 3D-Printed Vascular-Like Perfusion Tumor-on-a-Chip Recapitulates High-Grade Breast Cancer With in Vivo-Relevant Drug Resistance.Advanced healthcare materials · 2026Article
- Generalizability of an AI-based mammogram risk score (MRS) for breast cancer among diverse populations of women.Science advances · 2026Article
- Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index.Breast cancer research : BCR · 2025Article
- Causal Effects of Breast Cancer Risk Factors across Hormone Receptor Breast Cancer Subtypes: A Two-Sample Mendelian Randomization Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Mammographic density and breast cancer risk among Black American women.International journal of cancer · 2025Article
- Permutation Test for Image-on-Scalar Regression With an Application to Breast Cancer.Statistics in medicine · 2024Article
- Mammographic density mediates the protective effect of early-life body size on breast cancer risk.Nature communications · 2024Article
- The mediating role of mammographic density in the protective effect of early-life adiposity on breast cancer risk: a multivariable Mendelian randomization study.medRxiv : the preprint server for health sciences · 2023Article
- Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Correlation of Breast Density Grade on Mammogram With Diagnosed Breast Cancer: A Retrospective Cross-Sectional Study.Cureus · 2022Article
- Risk factors for breast cancer subtypes among Black women undergoing screening mammography.Breast cancer research and treatment · 2021Article
- Relationship of established risk factors with breast cancer subtypes.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeWe evaluated the association of percent mammographic density (PMD), absolute dense area (DA), and non-dense area (NDA) with risk of "intrinsic" molecular breast cancer (BC) subtypes.
methodsWe pooled 3492 invasive BC and 10,148 controls across six studies with density measures from prediagnostic, digitized film-screen mammograms. We classified BC tumors into subtypes [63% Luminal A, 21% Luminal B, 5% HER2 expressing, and 11% as triple negative (TN)] using information on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and tumor grade. We used polytomous logistic regression to calculate odds ratio (OR) and 95% confidence intervals (CI) for density measures (per SD) across the subtypes compared to controls, adjusting for age, body mass index and study, and examined differences by age group.
resultsAll density measures were similarly associated with BC risk across subtypes. Significant interaction of PMD by age (P = 0.001) was observed for Luminal A tumors, with stronger effect sizes seen for younger women < 45 years (OR = 1.69 per SD PMD) relative to women of older ages (OR = 1.53, ages 65-74, OR = 1.44 ages 75 +). Similar but opposite trends were seen for NDA by age for risk of Luminal A: risk for women: < 45 years (OR = 0.71 per SD NDA) was lower than older women (OR = 0.83 and OR = 0.84 for ages 65-74 and 75 + , respectively) (P < 0.001). Although not significant, similar patterns of associations were seen by age for TN cancers.
conclusionsMammographic density measures were associated with risk of all "intrinsic" molecular subtypes. However, findings of significant interactions between age and density measures may have implications for subtype-specific risk models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.